Anavar

Oxandrolone is a dihydrotestosterone (DHT)-derived anabolic steroid first synthesized in 1962 by Raphael Pappo at Searle Laboratories. It carries an oxygen atom substitution at the carbon-2 position of the A-ring, which confers exceptional oral bioavailability and resistance to hepatic metabolism. Among 17-alpha-alkylated oral anabolics, Oxandrolone exhibits the lowest degree of liver strain — a characteristic that underpins its clinical history in burn recovery, post-surgical muscle wasting, and Turner syndrome treatment.

Oxandrolone binds the androgen receptor with moderate affinity but exerts a disproportionately strong anabolic effect relative to its androgenic rating (anabolic:androgenic ratio of approximately 322–630:24). It does not aromatize to estrogen, meaning researchers will not encounter estrogen-mediated water retention or gynecomastia. Its mechanism favors nitrogen retention, phosphocreatine resynthesis, and direct adipocyte lipolysis — particularly in the abdominal and visceral compartments. Studies have demonstrated measurable reductions in total body fat even without dietary modification.

Anavar is valued in research protocols for lean tissue accrual, strength increases without corresponding bodyweight gain, and its favorable side-effect profile. It does not produce the dramatic mass of Dianabol or Anadrol, but what it adds tends to be retained post-cycle. Strength gains are reliable and often appear within the first week. Female researchers frequently select Oxandrolone because virilization risk remains low at conservative dosages.

This compound suits a wide range of experience levels. Novice researchers favor it for its predictability and mild side-effect profile. Intermediate and advanced researchers commonly incorporate it into cutting or recomposition protocols, often alongside a testosterone base. It pairs well with injectable compounds like Testosterone Enanthate, Primobolan, or Masteron for synergistic lean-tissue effects.

Oxandrolone has a half-life of approximately 9 hours, making twice-daily dosing (AM/PM split) optimal for stable blood concentrations. Typical research dosages range from 20–80 mg daily for males and 5–20 mg daily for females. While hepatotoxicity is the mildest of any 17-alpha-alkylated oral, liver-support supplementation (NAC, TUDCA) is still recommended during administration periods exceeding 6 weeks. Lipid panels should be monitored, as Oxandrolone has a measurable suppressive effect on HDL cholesterol.